Thursday - May 8, 2025
NASHVILLE, Tenn. / Apr 25, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update.
Conference Call Details: |
| |
Date: | Tuesday, May 14, 2024 | |
Time: | 8:00 a.m. Eastern time | |
Participant Dial-in: | 1-833-953-2434 (U.S.) | |
Replay Dial-in (Passcode 3093849): (telephonic replay through May 21, 2024) | 1-877-344-7529 (U.S.) | |
Webcast: (online replay through May 14, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$24.59 |
Daily Change: | 0.47 1.95 |
Daily Volume: | 307,870 |
Market Cap: | US$875.650M |
March 24, 2025 March 17, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load